title: What will replace TURP?
abstract: Benign prostatic hyperplasia (BPH) is almost ubiquitous.  About 25% to 40% of men in their lifetime will undergo treatment for BPH.  Surgical therapy produces in excess of 400,000 prostatectomies a year at a cost of more than 4 billion dollars.  Given the magnitude of the clinical problem and its overall impact on health care in the United States, the interest in alternatives to transurethral resection of the prostate (TURP) is intense.  From the panoply of contenders, the panel nominates those most likely to succeed.
authors.affiliation: Department of Urology, University of Washington, Seattle.
authors.forename: M K
authors.initials: MK
authors.lastname: Brawer
authors.forename: J D
authors.initials: JD
authors.lastname: McConnell
authors.forename: J E
authors.initials: JE
authors.lastname: Oesterling
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000726:Androgen Antagonists / Q000627:therapeutic use; D002404:Catheterization; D005544:Forecasting; D006801:Humans; D006979:Hyperthermia, Induced; D011468:Prostatectomy / Q000379:methods / Q000639:trends*; D011470:Prostatic Hyperplasia / Q000628:therapy*; D015607:Stents / Q000009:adverse effects; D016896:Treatment Outcome